Integra LifeSciences raises adj EPS guidance for Q4 and FY2022 above prior expectations

INTEGRA LIFESCIENCES HOLDINGS CORP

2022-FY EPS reported $2.16 revenue$1,557,666,000

Q4 2022 adjusted EPS expected $0.92-$0.96 vs $0.84 in Q4 2021; above Oct guidance high end.
FY 2022 adjusted EPS expected $3.34-$3.38 vs $3.18 in FY 2021; above Oct guidance high end.
Preliminary, unaudited results; full Q4 & FY 2022 earnings due Feb 22, 2023.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTEGRA LIFESCIENCES HOLDINGS CORP reported fourth quarter 2022 results: EPS $0.92 to $0.96. Guidance raised.

Period: fourth quarter 2022
EPS: $0.92 to $0.96
Guidance: raised
Result: preliminary results

Exact text from the filing

Fourth quarter 2022 adjusted earnings per diluted share is expected to be in a range of $0.92 to $0.96 compared to $0.84 in 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTEGRA LIFESCIENCES HOLDINGS CORP reported full-year 2022 results: EPS $3.34 to $3.38. Guidance raised.

Period: full-year 2022
EPS: $3.34 to $3.38
Guidance: raised
Result: preliminary results

Exact text from the filing

Full-year 2022 adjusted earnings per diluted share is expected to be in a range of $3.34 to $3.38 compared to $3.18 in 2021.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

INTEGRA LIFESCIENCES HOLDINGS CORP filing history →

Source: SEC EDGAR

accession 0000917520-23-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.